Abstract | BACKGROUND AND OBJECTIVES: DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study had 30 participants with AKI, which was defined as an increase in serum creatinine ≥ 0.3 mg/dl or ≥ 50% from baseline, and 30 controls from the general hospital wards and intensive care units. Plasma levels of C-terminal fibroblast growth factor 23 and vitamin D metabolites were measured within 24 hours of AKI onset and 5 days later. The composite endpoint was death or need for renal replacement therapy. RESULTS: CONCLUSIONS:
|
Authors | David E Leaf, Myles Wolf, Sushrut S Waikar, Herbert Chase, Marta Christov, Serge Cremers, Leonard Stern |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 7
Issue 8
Pg. 1217-23
(Aug 2012)
ISSN: 1555-905X [Electronic] United States |
PMID | 22700885
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- FGF23 protein, human
- PTH protein, human
- Parathyroid Hormone
- Phosphates
- Vitamin D
- Fibroblast Growth Factors
- 1,25-dihydroxyvitamin D
- Fibroblast Growth Factor-23
- 25-hydroxyvitamin D
- Creatinine
|
Topics |
- Acute Kidney Injury
(blood, diagnosis, mortality, therapy)
- Biomarkers
(blood)
- Case-Control Studies
- Creatinine
(blood)
- Female
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors
(blood)
- Hospital Mortality
- Humans
- Logistic Models
- Male
- Middle Aged
- Multivariate Analysis
- New York City
- Odds Ratio
- Parathyroid Hormone
(blood)
- Phosphates
(blood)
- Pilot Projects
- Prognosis
- Prospective Studies
- Renal Replacement Therapy
- Risk Assessment
- Risk Factors
- Time Factors
- Up-Regulation
- Vitamin D
(analogs & derivatives, blood)
|